Teva’s Duvakitug Shows 58% UC Remission, 55% CD Response in 44-Week Study
Teva Pharmaceutical and Sanofi’s RELIEVE UCCD extension study showed 58% of ulcerative colitis patients (900 mg) and 47% (450 mg) achieved clinical remission over 44 weeks, while Crohn’s disease endoscopic response rates were 55% and 41%. Duvakitug was well tolerated in 130 patients on 450 mg or 900 mg subcutaneous dosing every four weeks.
1. Study Design and Patient Population
The RELIEVE UCCD long-term extension enrolled 130 patients with initial response to duvakitug induction. Participants were re-randomized to receive 450 mg or 900 mg subcutaneous doses every four weeks, extending total exposure up to 58 weeks to assess durability of response.
2. Efficacy Results
In ulcerative colitis, 58% of patients on 900 mg and 47% on 450 mg achieved clinical remission at week 44. In Crohn’s disease, endoscopic response rates reached 55% with 900 mg and 41% with 450 mg, with consistent benefits across secondary efficacy measures.
3. Safety and Tolerability
Both dosing regimens were well tolerated, with no new safety signals emerging over the extension period. Adverse events remained consistent with earlier phases, supporting a favorable risk-benefit profile for continued development.
4. Analyst Outlook and Stock Reaction
Analysts at Goldman Sachs, Barclays and Scotiabank raised duvakitug price targets to $45, $38 and $40 respectively, lifting the consensus average to $31.75. Teva shares jumped 2.85% in premarket trading following the data release.